Pharvaris N.v.
A biopharmaceutical company developing oral pills for hereditary angioedema, a rare genetic disorder that causes sudden, painful swelling attacks. Its lead drug candidate, deucrictibant, aims to offer patients a pill instead of the injections they currently use. The company was founded in 2015 in Leiden, the Netherlands, when chemist Jochen Knolle—inventor of the injectable HAE drug icatibant—teamed up with colleagues to create an oral version of the same idea. The name blends "pharma" with a made-up suffix.
Sold 27.9K
Granted 35.3K · Sold 67.6K
Sold 42.4K
Sold 10.0K
Granted 70.0K · Sold 70.0K
Granted 7.3K · Sold 10.0K
Sold 10.0K
Sold 8.7K
Granted 10.0K · Sold 10.0K
Granted 5.3K · Sold 10.0K
Sold 9.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Modig BerndtChief Executive Officer, Director · 5 transactions | — | 3.12M | — | — | 27.9K |
| Lesage AnneChief Early Development · 20 transactions | — | 418.1K | 35.3K | — | 67.6K |
| Schikan Johannes Gerardus Christiaan PetrusDirector · 6 transactions | — | 352.8K | — | — | 42.4K |
| Nassif David W.CFO / CLO · 1 transaction | — | 120.3K | — | — | 10.0K |
| Lu PengChief Medical Officer · 23 transactions | — | 80.3K | 70.0K | — | 70.0K |
| Nijdam AnnaPrincipal Accounting Officer · 8 transactions | — | 46.3K | 7.3K | — | 10.0K |
| Souverijns WimChief Commercial Officer · 1 transaction | — | 45.1K | — | — | 10.0K |
| Abele Stefan AndreasChief Technical Ops Officer · 1 transaction | — | 35.2K | — | — | 8.7K |
| Bjork ElisabethDirector · 2 transactions | — | 25.2K | 10.0K | — | 10.0K |
| Glassman RobertDirector · 3 transactions | — | 10.5K | 5.3K | — | 10.0K |
| Monges VivianeDirector · 1 transaction | — | 5.5K | — | — | 9.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -276.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.